Chylothorax

Chylothorax
ICD-10	I89.8, J91
ICD-9	457.8, 511.9
DiseasesDB	29612
eMedicine	med/381
MeSH	D002916

WikiDoc Resources for Chylothorax
Articles
Most recent articles on Chylothorax Most cited articles on Chylothorax Review articles on Chylothorax Articles on Chylothorax in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Chylothorax Images of Chylothorax Photos of Chylothorax Podcasts & MP3s on Chylothorax Videos on Chylothorax
Evidence Based Medicine
Cochrane Collaboration on Chylothorax Bandolier on Chylothorax TRIP on Chylothorax
Clinical Trials
Ongoing Trials on Chylothorax at Clinical Trials.gov Trial results on Chylothorax Clinical Trials on Chylothorax at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Chylothorax NICE Guidance on Chylothorax NHS PRODIGY Guidance FDA on Chylothorax CDC on Chylothorax
Books
Books on Chylothorax
News
Chylothorax in the news Be alerted to news on Chylothorax News trends on Chylothorax
Commentary
Blogs on Chylothorax
Definitions
Definitions of Chylothorax
Patient Resources / Community
Patient resources on Chylothorax Discussion groups on Chylothorax Patient Handouts on Chylothorax Directions to Hospitals Treating Chylothorax Risk calculators and risk factors for Chylothorax
Healthcare Provider Resources
Symptoms of Chylothorax Causes & Risk Factors for Chylothorax Diagnostic studies for Chylothorax Treatment of Chylothorax
Continuing Medical Education (CME)
CME Programs on Chylothorax
International
Chylothorax en Espanol Chylothorax en Francais
Business
Chylothorax in the Marketplace Patents on Chylothorax
Experimental / Informatics
List of terms related to Chylothorax

Overview

Chylothorax, a type of pleural effusion is the accumulation of chyle in the pleural cavity secondary to destruction or obstruction of the thoracic duct or its tributaries.

Causes

Its cause is usually leakage from the thoracic duct or one of the main lymphatic vessels that drain to it. The most common causes are lymphoma and trauma caused by thoracic surgery. The effusion is characteristically white and milky in appearance and contains high levels of triglycerides.

In animals, chylothorax usually results from diseases that cause obstruction to the thoracic duct preventing lymph from draining normally into the venous system. Examples include tumors, heartworm disease, right sided cardiac failure, or idiopathic lymphangiectasia. The most effective form of treatment is surgical ligation of the thoracic duct combined with partial pericardectomy.

Differentiating chylothorax from other Diseasess

• Cirrhosis
• Congenital chylothorax
• Filariasis
• Iatrogenic
• Idiopathic
• Lymphoma
• Nonlymphomatous malignancies
• Nonsurgical penetrating trauma
• Tuberculosis

Epidemiology and Demographics

• The prevalence of [disease name] is approximately [number or range] per 100,000 individuals worldwide.
• In [year], the incidence of [disease name] was estimated to be [number or range] cases per 100,000 individuals in [location].

Age

• Patients of all age groups may develop [disease name].

• [Disease name] is more commonly observed among patients aged [age range] years old.
• [Disease name] is more commonly observed among [elderly patients/young patients/children].

Gender

• [Disease name] affects men and women equally.

• [Gender 1] are more commonly affected with [disease name] than [gender 2].
• The [gender 1] to [Gender 2] ratio is approximately [number > 1] to 1.

Race

• There is no racial predilection for [disease name].

• [Disease name] usually affects individuals of the [race 1] race.
• [Race 2] individuals are less likely to develop [disease name].

Risk Factors

Common risk factors in the development of Chylothorax] are

• Hepatectomy

Natural History, Complications and Prognosis

• The majority of patients with [disease name] remain asymptomatic for [duration/years].
• Early clinical features include [manifestation 1], [manifestation 2], and [manifestation 3].
• If left untreated, [#%] of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
• Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
• Prognosis is generally [excellent/good/poor], and the [1/5/10­year mortality/survival rate] of patients with [disease name] is approximately [#%].

Diagnosis

Diagnostic Study of Choice

• The diagnosis of [disease name] is made when at least [number] of the following [number] diagnostic criteria are met:

• [criterion 1]
• [criterion 2]
• [criterion 3]
• [criterion 4]

History and Symptoms

• [Disease name] is usually asymptomatic.
• Symptoms of [disease name] may include the following:

• [symptom 1]
• [symptom 2]
• [symptom 3]
• [symptom 4]
• [symptom 5]
• [symptom 6]

Physical Examination

• Patients with [disease name] usually appear [general appearance].
• Physical examination may be remarkable for:

• [finding 1]
• [finding 2]
• [finding 3]
• [finding 4]
• [finding 5]
• [finding 6]

Laboratory Findings

There are no specific laboratory findings associated with chylothorax.

• An elevated concentration of pleural fluid triglyceride >110 mg/dL is diagnostic of chylothorax.

Other Imaging Findings

• There are no [imaging study] findings associated with [disease name].

Other diagnostic studies for chylothorax include

• Lymphangiography which demonstrates extravasation into the pleural space.

Other Diagnostic Studies

• [Disease name] may also be diagnosed using [diagnostic study name].
• Findings on [diagnostic study name] include [finding 1], [finding 2], and [finding 3].

Treatment

Medical Therapy

Chylothorax is a medical emergency and requires prompt treatment. Medical therapy for chylothorax include

• Total parenteral nutrition
• Octreotide injections

Surgery

Surgery is the mainstay of therapy for chylothorax

• Tube thoracostomy

Primary Prevention

• There are no primary preventive measures available for [disease name].

• Effective measures for the primary prevention of [disease name] include [measure1], [measure2], and [measure3].

• Once diagnosed and successfully treated, patients with [disease name] are followed-up every [duration]. Follow-up testing includes [test 1], [test 2], and [test 3].

See also

• Pleural effusion